Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8020641 | 1.00 | SLC7A5 (0.59) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL321221 | 0.98 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL4279625 | 0.98 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL1938136 | 0.97 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL1938140 | 0.97 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL525092 | 0.94 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL525094 | 0.94 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8333097 | 0.92 | SLC7A5 (0.54) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8333110 | 0.92 | SLC7A5 (0.54) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL27680265 | 0.90 | SLC7A5 (0.67) | SLC7A5TAAR1SLC6A2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102355-A1 | ORAL PREPARATION COMPRISING CHICORY DIETARY FIBER OR CASSAVA STARCH | LG H&H CO., LTD. (KR) | 2026-04-16 | — | — | US | disclosed |
| US-20250340743-A1 | Polyetheramine-Based Multifunctional Booster | TROY TECH II INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4535999-A1 | POLYETHERAMINE-BASED MULTIFUNCTIONAL BOOSTER COMPOSITIONS | Troy Technology II, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024147490-A1 | ORAL PREPARATION COMPRISING CHICORY FIBER OR CASSAVA STARCH | 주식회사 엘지생활건강 | 2024-07-11 | — | — | WO | disclosed |
| EP-0971686-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN | The Boots Company PLC (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998044904-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN | THE BOOTS COMPANY PLC (GB) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102355-A1 | ORAL PREPARATION COMPRISING CHICORY DIETARY FIBER OR CASSAVA STARCH | SI, TAS2R41, TAS2R14 | SLC7A5 3790/4885TAAR1 4460/4885SLC6A2 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.